Among patients with allergic rhinitis (AR), very often sneezing subsides, itching improves, and rhinorrhoea becomes manageable, yet nasal congestion continues to interfere with breathing and sleep. In search of faster relief, patients may repeatedly use over-the-counter nasal decongestant sprays, sometimes without recognising that prolonged use can contribute to the very obstruction they are trying to relieve (1).

Persistent nasal congestion, therefore, warrants careful clinical evaluation to determine whether allergic inflammation remains inadequately controlled or the treatment itself is contributing to the problem. The distinction matters because managing persistent obstruction requires more than simply adding another medication. It calls for reassessing the underlying cause, reviewing existing treatment and identifying patients who may benefit from additional symptom-directed therapy. (1)

Why Does Nasal Obstruction Persist Despite Allergy Treatment?

Nasal congestion is not driven by histamine alone. Allergic inflammation involves several mediators that contribute to mucosal oedema, vascular engorgement and increased nasal airway resistance. Consequently, patients may experience improvement in sneezing, itching and rhinorrhoea with oral H1-antihistamines while continuing to report troublesome obstruction. (1)

Persistent symptoms may also reflect poor treatment adherence, incorrect intranasal spray technique, ongoing allergen exposure or coexisting conditions such as chronic rhinosinusitis, nasal polyps and structural nasal abnormalities (1). For patients with persistent AR, intranasal corticosteroids remain an important treatment option because they address the underlying inflammatory process. Combination intranasal antihistamine–corticosteroid therapy may offer additional symptom control when clinically indicated. (1,2)

However, when patients increasingly rely on rapid-acting decongestant sprays, a different problem warrants attention.

The Decongestant Trap: When Relief Intervention Leads to Rebound Nasal Congestion

Topical nasal decongestants such as oxymetazoline and xylometazoline provide rapid relief by constricting blood vessels in the nasal mucosa (1,3). Their immediate effect can make them particularly appealing to patients struggling with persistent blockage (1). However, repeated or prolonged use may lead to rhinitis medicamentosa, a form of drug-induced rhinitis characterised by rebound nasal congestion (1,3). Patients may initially experience satisfactory relief, but over time, congestion can return as the medication's effect diminishes (1). This may encourage more frequent administration, creating a cycle of recurrent obstruction and repeated spray use (1,3).

The International Consensus Statement on Allergy and Rhinology (ICAR-AR 2023) recognises rhinitis medicamentosa as a complication of prolonged topical decongestant use. Although the precise exposure threshold remains uncertain, rebound effects have been reported after only a few days, and chronic use is discouraged. (1) Importantly, rhinitis medicamentosa may coexist with allergic rhinitis, making it difficult to distinguish uncontrolled allergy from medication-related obstruction without a careful treatment history (1,3).

Recognising and Breaking the Cycle of Nasal Congestion

Persistent nasal obstruction in a patient frequently using topical decongestants should prompt clinicians to assess the duration and frequency of spray use (1,3). Management primarily involves discontinuing the offending decongestant while addressing underlying nasal inflammation. Patients should be counselled that congestion may temporarily worsen during withdrawal. Intranasal corticosteroids are commonly used to help manage rebound symptoms, while saline irrigation may provide supportive relief. Treatment should also address any underlying allergic or anatomical contributors that initially prompted decongestant use. (1,3)

Beyond Topical Sprays: The Role of Oral Fexofenadine–Pseudoephedrine

In selected patients with allergic rhinitis, troublesome congestion may coexist with sneezing, itching and rhinorrhoea, creating a need to address both inflammatory symptoms and nasal obstruction (1,4).

Fexofenadine, a second-generation H1-antihistamine, helps control histamine-mediated allergic symptoms, while pseudoephedrine acts as an oral sympathomimetic decongestant, reducing nasal mucosal swelling through vasoconstriction (4,5,6). Clinical evidence has demonstrated a rapid onset of action with the fexofenadine–pseudoephedrine combination, with improvements in nasal airflow observed as early as 30 minutes and patient-reported relief of nasal obstruction beginning at 60 minutes (7).

Fexofenadine and Pseudoephedrine: Clinical Evidence Examining Complementary Effects

In a randomised, double-blind study involving 651 patients with seasonal allergic rhinitis, Sussman and colleagues evaluated fexofenadine hydrochloride 60 mg and sustained-release pseudoephedrine hydrochloride 120 mg, administered alone or in combination twice daily. The combination demonstrated significantly greater improvement in nasal congestion than fexofenadine monotherapy, while providing better relief of histamine-mediated symptoms than pseudoephedrine alone. (4) These findings suggest that fexofenadine–pseudoephedrine may provide more effective symptomatic relief when both antihistaminic and decongestant effects are required.

However, oral decongestants are not intended for routine long-term management. The 2026 ARIA-EAACI guidance retains earlier recommendations against regular use of oral antihistamine- decongestant combinations (5).

Pseudoephedrine also requires appropriate patient selection because of potential cardiovascular and central nervous system adverse effects. It is contraindicated in certain conditions, including severe hypertension and severe coronary artery disease, and requires caution in patients with other related comorbidities. (6)

Individualised Approach to Persistent Nasal Congestion Requires Clinician’s Acumen

Persistent nasal congestion does not always indicate inadequate antihistamine efficacy. It may reflect uncontrolled allergic inflammation, coexisting nasal disease or rebound congestion associated with topical decongestant overuse (1,3). For clinicians, distinguishing these possibilities is essential to avoiding unnecessary treatment escalation. While fexofenadine–pseudoephedrine may have a role in short-term symptom management for appropriately selected patients (4,5,6), sustained control depends on treating underlying inflammation, recognising decongestant overuse and individualising therapy according to clinical need and safety considerations (1,2,3,5).

Key Points

  •  Persistent nasal congestion in allergic rhinitis may result from uncontrolled inflammation, coexisting nasal conditions or medication overuse, highlighting the need for careful clinical evaluation.
  •  Prolonged use of topical nasal decongestants may cause rhinitis medicamentosa, leading to rebound congestion. Management involves discontinuing the offending spray and addressing underlying inflammation.
  •  Fexofenadine–pseudoephedrine may provide short-term relief of allergic symptoms and nasal obstruction in selected patients with allergic rhinitis.


Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .